VICTORY: Merck's Zontivity 1st PAR-1 antiplatelet OK'd in US
This article was originally published in Scrip
Executive Summary
After gaining the backing of an FDA panel of experts in January, it was highly likely Merck would win US regulators' blessing to market Zontivity (vorapaxar) – a drug once thought dead in the water – as an adjunctive therapy to reduce atherothrombotic events in patients with a history of myocardial infarction (MI), although there was some skepticism on the part of the agency's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) on the firm's data.